What Can Abbott Lab Shareholders Expect From the Recent Break Up?

“Drug and medical stocks are not generally thought of as stocks hitting 52-week highs by the investing public.  So what about when a company decides to unlock shareholder value by breaking itself up?  Abbott Laboratories (NYSE: ABT) is company which we noted one day could become the next mega-cap ($100 billion in value), but now the company is breaking itself up into two companies.

The first bit of news is that the $1.18 EPS report was a penny ahead of expectations, but other reports were calling the earnings a miss.  The larger news is of the company’s break-up whereby it will spin off its drug unit.  Zacks has outlined its take on the break-up as well with a current “Neutral” rating. ….”

Full article